Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.

Abstract: A method is provided for manipulating objects in a cavity including a liquid, the method including providing in at least one region of the cavity objects capable of absorbing light in a given wavelength range, forming an aggregate of the objects by submitting them to an acoustic field, and disrupting the aggregate by submitting the aggregate to a light beam emitting at the given wavelength range. Also provided is a device for manipulating objects.

Abstract: A method for constructing a high-resolution merged signal from low-resolution signals acquired by an acquisition device includes acquisition of low-resolution signals (BR), measurement and/or estimation of acquisition parameters, pre-merging of the signals as a function of the low-resolution signals and of the parameters, filtering of the pre-merged signal, transmission of the filtered pre-merged signal and of the parameters, calculation of an estimate of the pre-merged signal by an inverse filtering of the filtered pre-merged signal, and determination, according to a variational method, of the high-resolution merged signal from the estimate of the pre-merged signal and of the parameters, a resolution of the merged signal is greater than a resolution of each signal.

Abstract: The present invention aims at improving the Doppler imaging of a biological sample comprising blood. For this, it is proposed a method for imaging a biological sample (10), the sample (10) comprising blood (14) comprising diffusors and solid tissue (16), the method comprising obtaining observation, each observation being characterized by a different point spread function associating a signal to each location of the region of interest, the signal comprising a first contribution representative of the diffusors of blood vessels within the location, a second contribution representative of the tissue diffusors and a third contribution representative of blood signal associated to blood diffusors outside of the location, and estimating, for each location, the blood flow by using a statistical analysis.

Abstract: The present invention relates to a compound of the following formula (I). The invention also relates to uses thereof as a chromophore as such or for building pigments displaying special optical effects, including metal-like reflection.

Abstract: A concentration sensor for at least one biological species in the blood includes a support, at least one waveguide, and an optomechanical resonator suspended from the support. The optomechanical resonator is optically coupled to the waveguide, and the optomechanical resonator is configured to vibrate in volume mode and includes at least one face extending in the plane of the sensor and configured to receive molecules of the given species. At least the face includes a functionalisation layer specific to the species, the optomechanical resonator having a smaller dimension in a direction normal to the plane of the sensor compared with the dimensions of the said face.

Abstract: Disclosed are methods for diagnosing CAT1-related diseases, wherein the methods include detecting CAT1 in a cell by a BLV.RBD ligand, or a variant or a fragment thereof. Also disclosed is a BLV.RBD ligand, or a variant or a fragment thereof for use in the treatment of CAT1-related diseases and/or BLV infections.

Abstract: The present invention concerns a PTGDR-1 antagonist, a PTGDR-2 antagonist, a dual PTGDR-1/PTGDR-1 antagonist, or a combination of PTGDR-1 antagonist and PTGDR-2 antagonist, and pharmaceutical compositions containing them, for use for preventing and/or treating SLE.

Abstract: A 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of sickle cell disease in a patient in need thereof. Also, a 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the prevention and/or treatment of acute chest syndrome (ACS) in a sickle cell disease patient in need thereof.

Abstract: The invention relates to the extraction of organic compounds from mixtures of said compounds with water, using a nanoporous carbon membrane. The invention can be used in any field where it is desired to separate an organic compound of interest from water, such as the drying of alcohols or alkanes.

Abstract: The present invention relates to a method for preparing a porous scaffold for tissue engineering. It is another object of the present invention to provide a porous scaffold obtainable by the method as above described, and its use for tissue engineering, cell culture and cell delivery. The method of the invention comprises the steps consisting of: a) preparing an alkaline aqueous solution comprising an amount of at least one polysaccharide, an amount of a cross-linking agent and an amount of a porogen agent b) transforming the solution into a hydrogel by placing said solution at a temperature from about 4° C. to about 80° C. for a sufficient time to allow the cross-linking of said amount of polysaccharide and c) submerging said hydrogel into an aqueous solution d) washing the porous scaffold obtained at step c).

Abstract: The inventors have developed a metastatic 4T1 breast tumor model in BALB/c mice. They have shown that the vaccination with xenogeneic embryonic stem cells in combination with valproic acid (VPA) generates a higher anti-tumoral response against breast cancer and inhibits metastasis development. They established that these responses are achieved only by the addition of valproic acid in the therapeutic regimen in comparison to the use ESCs or iPSCs alone. Thus, the inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to i) a population of pluripotent cells and ii) a compound selected from a group which activates MHC expression, as a combined preparation for use in a method for treating a subject suffering from a cancer, comprising a step of administering simultaneously, separately or sequentially to said subject a therapeutically amount thereof.

Abstract: The present invention relates to a method for detecting or quantifying deoxyribonucleic acid (DNA) of human immunodeficiency virus 2 (HIV-2) in a sample containing DNA comprising: a) performing a real-time polymerase chain reaction (PCR) on the sample, or a fraction thereof comprising DNA, with at least two sets of primers and probe each respectively comprising two primers and a labeled probe for the detection or quantification of HIV-2 DNA, at least one of the sets is selected from the group consisting of: a set comprising a primer comprising or consisting of a sequence SEQ ID NO: 1 or a sequence having al least 90% identity to SEQ ID NO: 1, a primer comprising or consisting of a sequence SEQ ID NO: 2 or a sequence having 90% identity to SEQ ID NO: 2 or the complement of these sequences, and a labeled probe comprising or consisting of a sequence SEQ ID NO: 3, or a sequence having at least 90% identify to SEQ ID NO: 3 or the complement of these sequences, and a set comprising a primer comprising or consisting

Abstract: Disclosed are organic cation transporters (OCTs) inhibitors of Formula (A), as well as their pharmaceutically acceptable tautomers, salts or solvates. Also disclosed are pharmaceutical compositions including such OCTs inhibitor of Formula (A) and their use for treating and/or preventing mood-related disorders such as depressive disorders.

Abstract: The present invention relates to a composition comprising at least one poloxamer compound for use in the treatment of a fistula in an individual.

Abstract: The present invention relates to methods for adhering tissue surfaces and materials and biomedical uses thereof. In particular the present invention relates to a method for adhering a first tissue surface to a second tissue surface in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on at least one of the tissue surfaces, and approximating the surfaces for a time sufficient for allowing the surfaces to adhere to each other. The present invention also relates to a method for adhering a material to a biological tissue in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on the surface of the material and/or the biological tissue and approximating the material and the biological tissue for a time sufficient for allowing the material and the biological tissue to adhere to each other.

Abstract: The present invention relates to the treatment or prevention of skeletal disorders, at particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.